Comparison of Cases at the Time of Viremic Episode to the Corresponding Time Point on Antiretroviral Therapy (ART) (Controls), and to the Last Time Point on ART With Virologic Suppression Among Cases
| Characteristic . | Cases (n = 80) . | Controls (n = 87) . | P Value . |
|---|---|---|---|
| At time of VE/matched time point (cases and controls) | |||
| Duration on ART, wk, median | 47.2 | 47.1 | .687 |
| ≤24 | 6/80 (7.5) | 10/87 (11.5) | |
| >24–48 | 40/80 (50.0) | 36/87 (41.4) | |
| >48–72 | 26/80 (32.5) | 32/87 (36.8) | |
| >72 | 8/80 (10.0) | 9/87 (10.3) | |
| Mean VL, log10 copies/mL | 4.16 (n = 80) | 1.60 (n = 87) | |
| Proportion VL <50 copies/mL | 0/80 (0) | 86/87 (98.9) | |
| Any ARV detected in plasma | 15/80 (18.8) | 82/87 (94.3) | <.001 |
| TDF | 1/80 (1.3) | 76/87 (87.4) | <.001 |
| 3TC/FTC | 2/80 (2.5) | 79/87 (90.8) | <.001 |
| EFV | 13/80 (16.3) | 82/87 (94.3) | <.001 |
| Other | 1/80 (1.3) | 1/87 (1.2) | .959 |
| At preceding suppressed time point (cases only) | |||
| Duration on ART, wk, median | 39.5 | … | |
| ≤24 | 26/80 (32.5) | … | |
| 24–48 | 38/80 (47.5) | … | |
| 48–72 | 16/80 (20.0) | … | |
| Mean VL, log10 copies/mL | 1.69 (n = 80) | … | |
| Proportion VL <50 copies/mL | 70/80 (87.5) | … | |
| Any ARV detected in plasma | 72/80 (90.0) | … | |
| TDF | 36/80 (45.0) | … | |
| 3TC/FTC | 45/80 (56.3) | … | |
| EFV | 70/80 (87.5) | … | |
| Other | 2/80 (2.5) | … |
| Characteristic . | Cases (n = 80) . | Controls (n = 87) . | P Value . |
|---|---|---|---|
| At time of VE/matched time point (cases and controls) | |||
| Duration on ART, wk, median | 47.2 | 47.1 | .687 |
| ≤24 | 6/80 (7.5) | 10/87 (11.5) | |
| >24–48 | 40/80 (50.0) | 36/87 (41.4) | |
| >48–72 | 26/80 (32.5) | 32/87 (36.8) | |
| >72 | 8/80 (10.0) | 9/87 (10.3) | |
| Mean VL, log10 copies/mL | 4.16 (n = 80) | 1.60 (n = 87) | |
| Proportion VL <50 copies/mL | 0/80 (0) | 86/87 (98.9) | |
| Any ARV detected in plasma | 15/80 (18.8) | 82/87 (94.3) | <.001 |
| TDF | 1/80 (1.3) | 76/87 (87.4) | <.001 |
| 3TC/FTC | 2/80 (2.5) | 79/87 (90.8) | <.001 |
| EFV | 13/80 (16.3) | 82/87 (94.3) | <.001 |
| Other | 1/80 (1.3) | 1/87 (1.2) | .959 |
| At preceding suppressed time point (cases only) | |||
| Duration on ART, wk, median | 39.5 | … | |
| ≤24 | 26/80 (32.5) | … | |
| 24–48 | 38/80 (47.5) | … | |
| 48–72 | 16/80 (20.0) | … | |
| Mean VL, log10 copies/mL | 1.69 (n = 80) | … | |
| Proportion VL <50 copies/mL | 70/80 (87.5) | … | |
| Any ARV detected in plasma | 72/80 (90.0) | … | |
| TDF | 36/80 (45.0) | … | |
| 3TC/FTC | 45/80 (56.3) | … | |
| EFV | 70/80 (87.5) | … | |
| Other | 2/80 (2.5) | … |
Data are presented as no./No. (%) unless otherwise indicated.
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; ARV, antiretroviral; DRM, drug resistance mutation; EFV, efavirenz; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; VE, viremic episode; VL, viral load.
Comparison of Cases at the Time of Viremic Episode to the Corresponding Time Point on Antiretroviral Therapy (ART) (Controls), and to the Last Time Point on ART With Virologic Suppression Among Cases
| Characteristic . | Cases (n = 80) . | Controls (n = 87) . | P Value . |
|---|---|---|---|
| At time of VE/matched time point (cases and controls) | |||
| Duration on ART, wk, median | 47.2 | 47.1 | .687 |
| ≤24 | 6/80 (7.5) | 10/87 (11.5) | |
| >24–48 | 40/80 (50.0) | 36/87 (41.4) | |
| >48–72 | 26/80 (32.5) | 32/87 (36.8) | |
| >72 | 8/80 (10.0) | 9/87 (10.3) | |
| Mean VL, log10 copies/mL | 4.16 (n = 80) | 1.60 (n = 87) | |
| Proportion VL <50 copies/mL | 0/80 (0) | 86/87 (98.9) | |
| Any ARV detected in plasma | 15/80 (18.8) | 82/87 (94.3) | <.001 |
| TDF | 1/80 (1.3) | 76/87 (87.4) | <.001 |
| 3TC/FTC | 2/80 (2.5) | 79/87 (90.8) | <.001 |
| EFV | 13/80 (16.3) | 82/87 (94.3) | <.001 |
| Other | 1/80 (1.3) | 1/87 (1.2) | .959 |
| At preceding suppressed time point (cases only) | |||
| Duration on ART, wk, median | 39.5 | … | |
| ≤24 | 26/80 (32.5) | … | |
| 24–48 | 38/80 (47.5) | … | |
| 48–72 | 16/80 (20.0) | … | |
| Mean VL, log10 copies/mL | 1.69 (n = 80) | … | |
| Proportion VL <50 copies/mL | 70/80 (87.5) | … | |
| Any ARV detected in plasma | 72/80 (90.0) | … | |
| TDF | 36/80 (45.0) | … | |
| 3TC/FTC | 45/80 (56.3) | … | |
| EFV | 70/80 (87.5) | … | |
| Other | 2/80 (2.5) | … |
| Characteristic . | Cases (n = 80) . | Controls (n = 87) . | P Value . |
|---|---|---|---|
| At time of VE/matched time point (cases and controls) | |||
| Duration on ART, wk, median | 47.2 | 47.1 | .687 |
| ≤24 | 6/80 (7.5) | 10/87 (11.5) | |
| >24–48 | 40/80 (50.0) | 36/87 (41.4) | |
| >48–72 | 26/80 (32.5) | 32/87 (36.8) | |
| >72 | 8/80 (10.0) | 9/87 (10.3) | |
| Mean VL, log10 copies/mL | 4.16 (n = 80) | 1.60 (n = 87) | |
| Proportion VL <50 copies/mL | 0/80 (0) | 86/87 (98.9) | |
| Any ARV detected in plasma | 15/80 (18.8) | 82/87 (94.3) | <.001 |
| TDF | 1/80 (1.3) | 76/87 (87.4) | <.001 |
| 3TC/FTC | 2/80 (2.5) | 79/87 (90.8) | <.001 |
| EFV | 13/80 (16.3) | 82/87 (94.3) | <.001 |
| Other | 1/80 (1.3) | 1/87 (1.2) | .959 |
| At preceding suppressed time point (cases only) | |||
| Duration on ART, wk, median | 39.5 | … | |
| ≤24 | 26/80 (32.5) | … | |
| 24–48 | 38/80 (47.5) | … | |
| 48–72 | 16/80 (20.0) | … | |
| Mean VL, log10 copies/mL | 1.69 (n = 80) | … | |
| Proportion VL <50 copies/mL | 70/80 (87.5) | … | |
| Any ARV detected in plasma | 72/80 (90.0) | … | |
| TDF | 36/80 (45.0) | … | |
| 3TC/FTC | 45/80 (56.3) | … | |
| EFV | 70/80 (87.5) | … | |
| Other | 2/80 (2.5) | … |
Data are presented as no./No. (%) unless otherwise indicated.
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; ARV, antiretroviral; DRM, drug resistance mutation; EFV, efavirenz; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; VE, viremic episode; VL, viral load.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
